K36 Therapeutics, Inc., a clinical-stage biotech company focused on developing its MMSET inhibitor KTX-1001 for genetic translocation t(4;14) multiple myeloma, appointed Benjamin Winograd, chief medical officer to lead the medical and clinical teams. Winograd joins K36 with a track record of bringing innovative medicines for hematological and solid tumor disease treatments to patients.

Previously, Winograd worked at Celgene where, as vice president of clinical development and head of clinical hematology/oncology, he led the successful development and approval of transformative therapies REVLIMID, POMALYST and Abecma.

Winograd held roles at Schering Plough, Pharmacia and BMS that led to the approvals of Temodar and Taxol. Most recently, Winograd was the chief medical officer at Lava Therapeutics B.V. He brings over 30 years of industry experience to K36, and will lead clinical development, translational medicine, regulatory affairs, and medical affairs.

“Recruiting a leader with Dr. Winograd’s expertise, reputation and track record of advancing transformative therapies validates the potential opportunity that KTX-1001 will deliver,” said Terry Connolly, President and CEO of K36. “Benjamin will play an integral role in our continued advancement of the Phase 1 study of KTX-1001 and in supporting our translational medicine team in preparing for KTX-1001’s potential use in combination with other multiple myeloma standard-of-care agents, and in earlier lines of therapy.”

“K36 is embarking on a new precision medicine approach to personalized oral therapies that has the potential to transform the industry,” said Winograd. “The search for a selective MMSET inhibitor for myeloma patients has been ongoing for over a decade and I am excited to continue the development of KTX-1001 for multiple myeloma in high-risk patients with translocation t(4;14) and to explore additional unmet needs in solid tumors.”

K36 also appointed Soo Bang senior vice president of strategy and operations, Erin Flynt, executive director of translational medicine, Sanjana Miskin director of clinical science, Julie Vazquez director of clinical operations, and Lan Xu, PhD, as vice president of preclinical and translational development.